Evidence map›Paper›PMID 42020496›Full record

ArticleScientific reports2026

Comparison of a swept-source optical coherence tomograph device (MT9000) to a partial coherence interferometry-based biometer (IOLMaster 500) in a high-altitude environment.

Yonglin Chen, Rong Hu, Yongguo Xiang, Hong Cheng, Liang Liang, Juan Kang, Shuren Pan, Ke Hu, Shijie Zheng

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yonglin Chen *The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China.
Rong Hu *The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China.
Yongguo XiangThe First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China.
Hong ChengThe First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China.
Liang LiangChangdu People's Hospital of Xizang, Qamdo, China.
Juan KangChangdu People's Hospital of Xizang, Qamdo, China.
Shuren PanChangdu People's Hospital of Xizang, Qamdo, China.
Ke HuThe First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China. cqhuke@hospital.cqmu.edu.cn.
Shijie ZhengThe First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Prevention and Treatment on Major Blinding Diseases, Chongqing Eye Institute, Chongqing Branch (Municipality Division) of National Clinical Research Center for Ocular Diseases, Chongqing, China. zhengshijie@126.com.

Funding

Chongqing medical scientific research project (Joint project of Chongqing Health Commission and Science and Technology Bureau) 2024ZDXM033National Natural Science Foundation of China 82371098the Natural Science Foundation of Tibet Autonomous Region XZ22025ZR-ZY080(Z)
6 · The paper itself

Abstract

To evaluate the agreement of biometry parameters of cataract patients between MT9000 (Vision Micro Image (Henan) Technology Co., Ltd.) and IOLMaster 500 (Carl Zeiss Meditec, Jena, Germany) in a high-altitude environment. A total of 145 eyes from the high-altitude region and 207 eyes from the low-altitude region had biometry measurements using MT9000 and IOLMaster 500. Axial length (AL), anterior chamber depth (ACD), white-to-white length (WTW), and keratometry (K1, K2, and Ke) values were obtained by both devices. Agreement was assessed based on intralclass correlation coefficient (ICC) and Bland–Altman analysis by calculating the mean difference and 95% limits of agreement (LoA). Propensity score matching analysis was used to control for age, sex, and AL among populations at different altitudes. The ICC values and the LOA ranges measured by the two devices for AL, ACD, WTW, and K(K1, K2, and Ke) were 0.996, 0.799, 0.660, 0.976, 0.967, 0.978, and 0.055 to 0.148 mm, -0.499 to 0.217 mm, -0.443 to 0.552mm, -0.636 to 0.615mm, -0.785 to 0.793mm, -0.595 to 0.609mm, respectively. The differences among different cataract grade groups and different altitude groups were not statistically significant (P > 0.05). MT9000 and IOLMaster 500 showed excellent agreement in measuring AL and K(K1, K2, and Ke), good agreement in measuring ACD, and moderate agreement in measuring WTW in cataract patients in high-altitude environments. Although there were statistically significant differences, the magnitudes were below clinically significant thresholds. In situations requiring precise ACD and WTW measurement, MT9000 cannot replace IOLMaster 500.

Indexed as

AltitudeAxial lengthImagingKeratometryMT9000

Identifiers

PMID42020496
PMCPMC13273181

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.